Business
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"\n 25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial operations with (Z)-endoxifen\n \n \n SEATTLE, Oct. 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (\"Atossa\" or the \"Company\"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science businesses. He has overseen weekly revenue forecasting in partnership with commercial leadership, managed operating expense budgets exceeding $200M, implemented and certified Sarbanes-Oxley (SOX) controls, and led programs delivering over $50M in cost savings.\n \n \n \n \n \n \n \n Mr. Daniel also brings deep treasury and capital-markets expertise relevant to Atossa's transition from clinical development to commercialization. He has managed a $400M cash and investments portfolio and helped execute nearly $1 billion in equity, convertible debt, and credit transactions across varying market conditions; experience that will inform Atossa's balanced approach to financing growth while maintaining discipline.\n \"As we prepare to evolve into a commercial company, we're focused on three things: revenue-ready systems, disciplined spend, and milestone-aligned financing,\" said Steven Quay, M.D., Ph.D., Atossa Chairman and Chief Executive Officer. \"Mark has built and run that playbook in public life-science companies, standing up weekly revenue forecasts with sales, installing ERP/BI visibility from bookings to cash, tightening controls, and ensuring liquidity through volatile markets. His skill set is exactly what we need to support the planned launch path for (Z)-endoxifen.\"\n \"I'm excited to help Atossa operationalize commercial readiness—from FP&A cadence and revenue forecasting to capital planning and investor engagement,\" said Mr. Daniel. \"Our aim is to align spending with value-creating milestones, strengthen the systems that support scale, and pursue a balanced financing strategy to enable a high-quality, efficient market...